SIRGs score may be a predictor of prognosis and immunotherapy response for esophagogastric junction adenocarcinoma
BackgroundEsophagogastric junction adenocarcinoma (EGJA) is a special malignant tumor with unknown biological behavior. PD-1 checkpoint inhibitors have been recommended as first-line treatment for advanced EGJA patients. However, the biomarkers for predicting immunotherapy response remain controvers...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.977894/full |
| _version_ | 1811215272792555520 |
|---|---|
| author | Li-Ying OuYang Zi-Jian Deng Zi-Jian Deng Zi-Jian Deng Yu-Feng You Jia-Ming Fang Jia-Ming Fang Jia-Ming Fang Xi-Jie Chen Xi-Jie Chen Xi-Jie Chen Jun-Jie Liu Jun-Jie Liu Jun-Jie Liu Xian-Zhe Li Xian-Zhe Li Xian-Zhe Li Lei Lian Lei Lian Lei Lian Shi Chen Shi Chen Shi Chen |
| author_facet | Li-Ying OuYang Zi-Jian Deng Zi-Jian Deng Zi-Jian Deng Yu-Feng You Jia-Ming Fang Jia-Ming Fang Jia-Ming Fang Xi-Jie Chen Xi-Jie Chen Xi-Jie Chen Jun-Jie Liu Jun-Jie Liu Jun-Jie Liu Xian-Zhe Li Xian-Zhe Li Xian-Zhe Li Lei Lian Lei Lian Lei Lian Shi Chen Shi Chen Shi Chen |
| author_sort | Li-Ying OuYang |
| collection | DOAJ |
| description | BackgroundEsophagogastric junction adenocarcinoma (EGJA) is a special malignant tumor with unknown biological behavior. PD-1 checkpoint inhibitors have been recommended as first-line treatment for advanced EGJA patients. However, the biomarkers for predicting immunotherapy response remain controversial.MethodsWe identified stromal immune-related genes (SIRGs) by ESTIMATE from the TCGA-EGJA dataset and constructed a signature score. In addition, survival analysis was performed in both the TCGA cohort and GEO cohort. Subsequently, we explored the differences in tumor-infiltrating immune cells, immune subtypes, immune-related functions, tumor mutation burden (TMB), immune checkpoint gene expression, immunophenoscore (IPS) between the high SIRGs score and low SIRGs score groups. Finally, two validation cohorts of patients who had accepted immunotherapy was used to verify the value of SIRGs score in predicting immunotherapy response.ResultsEight of the SIRGs were selected by LASSO regression to construct a signature score (SIRGs score). Univariate and multivariate analyses in the TCGA and GEO cohort suggested that SIRGs score was an independent risk factor for the overall survival (OS) and it could increase the accuracy of clinical prediction models for survival. However, in the high SIRGs score group, patients had more immune cell infiltration, more active immune-related functions, higher immune checkpoint gene expression and higher IPS-PD1 and IPS-PD1-CTLA4 scores, which indicate a better response to immunotherapy. The external validation illustrated that high SIRGs score was significantly associated with immunotherapy response and immune checkpoint inhibitors (ICIs) can improve OS in patients with high SIRGs score.ConclusionThe SIRGs score may be a predictor of the prognosis and immune-therapy response for esophagogastric junction adenocarcinoma. |
| first_indexed | 2024-04-12T06:18:47Z |
| format | Article |
| id | doaj.art-f1d268a71b8746808038212dc846ad98 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-12T06:18:47Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-f1d268a71b8746808038212dc846ad982022-12-22T03:44:23ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-08-011310.3389/fimmu.2022.977894977894SIRGs score may be a predictor of prognosis and immunotherapy response for esophagogastric junction adenocarcinomaLi-Ying OuYang0Zi-Jian Deng1Zi-Jian Deng2Zi-Jian Deng3Yu-Feng You4Jia-Ming Fang5Jia-Ming Fang6Jia-Ming Fang7Xi-Jie Chen8Xi-Jie Chen9Xi-Jie Chen10Jun-Jie Liu11Jun-Jie Liu12Jun-Jie Liu13Xian-Zhe Li14Xian-Zhe Li15Xian-Zhe Li16Lei Lian17Lei Lian18Lei Lian19Shi Chen20Shi Chen21Shi Chen22Department of Intensive Care Unit, Sun Yat-Sen University Cancer Center, Guangzhou, ChinaDepartment of Gastrointestinal Surgery, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, ChinaGuangdong Institute of Gastroenterology, Guangzhou, ChinaGuangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Guangzhou, ChinaSchool of Medicine, Sun Yat-Sen University, Guangzhou, ChinaDepartment of Gastrointestinal Surgery, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, ChinaGuangdong Institute of Gastroenterology, Guangzhou, ChinaGuangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Guangzhou, ChinaDepartment of Gastrointestinal Surgery, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, ChinaGuangdong Institute of Gastroenterology, Guangzhou, ChinaGuangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Guangzhou, ChinaDepartment of Gastrointestinal Surgery, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, ChinaGuangdong Institute of Gastroenterology, Guangzhou, ChinaGuangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Guangzhou, ChinaDepartment of Gastrointestinal Surgery, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, ChinaGuangdong Institute of Gastroenterology, Guangzhou, ChinaGuangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Guangzhou, ChinaDepartment of Gastrointestinal Surgery, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, ChinaGuangdong Institute of Gastroenterology, Guangzhou, ChinaGuangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Guangzhou, ChinaDepartment of Gastrointestinal Surgery, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, ChinaGuangdong Institute of Gastroenterology, Guangzhou, ChinaGuangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Guangzhou, ChinaBackgroundEsophagogastric junction adenocarcinoma (EGJA) is a special malignant tumor with unknown biological behavior. PD-1 checkpoint inhibitors have been recommended as first-line treatment for advanced EGJA patients. However, the biomarkers for predicting immunotherapy response remain controversial.MethodsWe identified stromal immune-related genes (SIRGs) by ESTIMATE from the TCGA-EGJA dataset and constructed a signature score. In addition, survival analysis was performed in both the TCGA cohort and GEO cohort. Subsequently, we explored the differences in tumor-infiltrating immune cells, immune subtypes, immune-related functions, tumor mutation burden (TMB), immune checkpoint gene expression, immunophenoscore (IPS) between the high SIRGs score and low SIRGs score groups. Finally, two validation cohorts of patients who had accepted immunotherapy was used to verify the value of SIRGs score in predicting immunotherapy response.ResultsEight of the SIRGs were selected by LASSO regression to construct a signature score (SIRGs score). Univariate and multivariate analyses in the TCGA and GEO cohort suggested that SIRGs score was an independent risk factor for the overall survival (OS) and it could increase the accuracy of clinical prediction models for survival. However, in the high SIRGs score group, patients had more immune cell infiltration, more active immune-related functions, higher immune checkpoint gene expression and higher IPS-PD1 and IPS-PD1-CTLA4 scores, which indicate a better response to immunotherapy. The external validation illustrated that high SIRGs score was significantly associated with immunotherapy response and immune checkpoint inhibitors (ICIs) can improve OS in patients with high SIRGs score.ConclusionThe SIRGs score may be a predictor of the prognosis and immune-therapy response for esophagogastric junction adenocarcinoma.https://www.frontiersin.org/articles/10.3389/fimmu.2022.977894/fullesophagogastric junction adenocarcinomaSIRGs scoreprognosisimmunotherapytumor microenvironment |
| spellingShingle | Li-Ying OuYang Zi-Jian Deng Zi-Jian Deng Zi-Jian Deng Yu-Feng You Jia-Ming Fang Jia-Ming Fang Jia-Ming Fang Xi-Jie Chen Xi-Jie Chen Xi-Jie Chen Jun-Jie Liu Jun-Jie Liu Jun-Jie Liu Xian-Zhe Li Xian-Zhe Li Xian-Zhe Li Lei Lian Lei Lian Lei Lian Shi Chen Shi Chen Shi Chen SIRGs score may be a predictor of prognosis and immunotherapy response for esophagogastric junction adenocarcinoma Frontiers in Immunology esophagogastric junction adenocarcinoma SIRGs score prognosis immunotherapy tumor microenvironment |
| title | SIRGs score may be a predictor of prognosis and immunotherapy response for esophagogastric junction adenocarcinoma |
| title_full | SIRGs score may be a predictor of prognosis and immunotherapy response for esophagogastric junction adenocarcinoma |
| title_fullStr | SIRGs score may be a predictor of prognosis and immunotherapy response for esophagogastric junction adenocarcinoma |
| title_full_unstemmed | SIRGs score may be a predictor of prognosis and immunotherapy response for esophagogastric junction adenocarcinoma |
| title_short | SIRGs score may be a predictor of prognosis and immunotherapy response for esophagogastric junction adenocarcinoma |
| title_sort | sirgs score may be a predictor of prognosis and immunotherapy response for esophagogastric junction adenocarcinoma |
| topic | esophagogastric junction adenocarcinoma SIRGs score prognosis immunotherapy tumor microenvironment |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.977894/full |
| work_keys_str_mv | AT liyingouyang sirgsscoremaybeapredictorofprognosisandimmunotherapyresponseforesophagogastricjunctionadenocarcinoma AT zijiandeng sirgsscoremaybeapredictorofprognosisandimmunotherapyresponseforesophagogastricjunctionadenocarcinoma AT zijiandeng sirgsscoremaybeapredictorofprognosisandimmunotherapyresponseforesophagogastricjunctionadenocarcinoma AT zijiandeng sirgsscoremaybeapredictorofprognosisandimmunotherapyresponseforesophagogastricjunctionadenocarcinoma AT yufengyou sirgsscoremaybeapredictorofprognosisandimmunotherapyresponseforesophagogastricjunctionadenocarcinoma AT jiamingfang sirgsscoremaybeapredictorofprognosisandimmunotherapyresponseforesophagogastricjunctionadenocarcinoma AT jiamingfang sirgsscoremaybeapredictorofprognosisandimmunotherapyresponseforesophagogastricjunctionadenocarcinoma AT jiamingfang sirgsscoremaybeapredictorofprognosisandimmunotherapyresponseforesophagogastricjunctionadenocarcinoma AT xijiechen sirgsscoremaybeapredictorofprognosisandimmunotherapyresponseforesophagogastricjunctionadenocarcinoma AT xijiechen sirgsscoremaybeapredictorofprognosisandimmunotherapyresponseforesophagogastricjunctionadenocarcinoma AT xijiechen sirgsscoremaybeapredictorofprognosisandimmunotherapyresponseforesophagogastricjunctionadenocarcinoma AT junjieliu sirgsscoremaybeapredictorofprognosisandimmunotherapyresponseforesophagogastricjunctionadenocarcinoma AT junjieliu sirgsscoremaybeapredictorofprognosisandimmunotherapyresponseforesophagogastricjunctionadenocarcinoma AT junjieliu sirgsscoremaybeapredictorofprognosisandimmunotherapyresponseforesophagogastricjunctionadenocarcinoma AT xianzheli sirgsscoremaybeapredictorofprognosisandimmunotherapyresponseforesophagogastricjunctionadenocarcinoma AT xianzheli sirgsscoremaybeapredictorofprognosisandimmunotherapyresponseforesophagogastricjunctionadenocarcinoma AT xianzheli sirgsscoremaybeapredictorofprognosisandimmunotherapyresponseforesophagogastricjunctionadenocarcinoma AT leilian sirgsscoremaybeapredictorofprognosisandimmunotherapyresponseforesophagogastricjunctionadenocarcinoma AT leilian sirgsscoremaybeapredictorofprognosisandimmunotherapyresponseforesophagogastricjunctionadenocarcinoma AT leilian sirgsscoremaybeapredictorofprognosisandimmunotherapyresponseforesophagogastricjunctionadenocarcinoma AT shichen sirgsscoremaybeapredictorofprognosisandimmunotherapyresponseforesophagogastricjunctionadenocarcinoma AT shichen sirgsscoremaybeapredictorofprognosisandimmunotherapyresponseforesophagogastricjunctionadenocarcinoma AT shichen sirgsscoremaybeapredictorofprognosisandimmunotherapyresponseforesophagogastricjunctionadenocarcinoma |